Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection in patients with female pattern hair loss: a prospective cohort study.
Metabolic syndrome
dutasteride
hair loss
trichoscope
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
pubmed:
24
12
2019
medline:
26
11
2021
entrez:
24
12
2019
Statut:
ppublish
Résumé
No studies investigating the impact of metabolic syndrome (MetS) in treatment response of female pattern hair loss (FPHL). In this prospective cohort study, we studied the impact of MetS in response to intradermal dutasteride 0.02% injection in patients with FPHL. Fifty-one adult participants with FPHL were classified into study cohorts: with MetS and comparison cohorts without MetS. Both groups underwent clinical, trichoschopic, and digital folliscopic evaluation. Treatment was scheduled over a period of 3 months as four weekly sessions, followed by another four bimonthly sessions. Response was evaluated by digital folliscopy, investigator's, and patient's self assessments at 1 and 3 months post-treatment. Side effects were evaluated. In participants with MetS, there was a significant reduction of the mean percentage of terminal hair with significant increase of the mean percentage of vellus hair ( MetS negatively impacted FPHL in terms of response to intradermal injection of dutasteride 0.02% and severity. Further studies are still needed.
Sections du résumé
BACKGROUND
BACKGROUND
No studies investigating the impact of metabolic syndrome (MetS) in treatment response of female pattern hair loss (FPHL).
OBJECTIVE
OBJECTIVE
In this prospective cohort study, we studied the impact of MetS in response to intradermal dutasteride 0.02% injection in patients with FPHL.
METHODS
METHODS
Fifty-one adult participants with FPHL were classified into study cohorts: with MetS and comparison cohorts without MetS. Both groups underwent clinical, trichoschopic, and digital folliscopic evaluation. Treatment was scheduled over a period of 3 months as four weekly sessions, followed by another four bimonthly sessions. Response was evaluated by digital folliscopy, investigator's, and patient's self assessments at 1 and 3 months post-treatment. Side effects were evaluated.
RESULTS
RESULTS
In participants with MetS, there was a significant reduction of the mean percentage of terminal hair with significant increase of the mean percentage of vellus hair (
CONCLUSIONS
CONCLUSIONS
MetS negatively impacted FPHL in terms of response to intradermal injection of dutasteride 0.02% and severity. Further studies are still needed.
Identifiants
pubmed: 31868049
doi: 10.1080/09546634.2019.1708849
doi:
Substances chimiques
Dutasteride
O0J6XJN02I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM